Geometric Isomer of Guanabenz Confers Hepatoprotection to a Murine Model of Acetaminophen Toxicity

Overdose of acetaminophen, a widely used antipyretic and analgesic drug, is one of the leading causes of drug-induced acute liver injury in the United States and worldwide. Phase-I metabolism of acetaminophen generates the toxic N-acetyl-p-benzoquinone imine (NAPQI) intermediate. Reactions of NAPQI with a wide range of biomolecules cause increased oxidative stress, endoplasmic reticulum (ER) stress, inflammation, and mitochondrial dysfunction, some of the cellular events contributing toward liver toxicity. Previously, we evaluated the potential of an FDA-approved, ER stress-modulating antihypertensive drug, Wytensin (trans-guanabenz, E-GA), as an antidote for acetaminophen hepatotoxicity. E-GA prevented elevation of the liver enzyme alanine aminotransferase (ALT), even when administered up to 6 h after acetaminophen overdose, and exhibited synergistic analgesic interactions. However, the commercially available guanabenz exists solely as a trans-isomer and suffers from sedative side effects resulting from the inhibition of central α2A-adrenergic receptors in locus coeruleus. Here, we studied the utility of the relatively unexplored cis-isomer of guanabenz as a treatment option for acetaminophen-induced liver toxicity. cis(Z)-Guanabenz acetate (Z-GA) lacks interaction with α2A-adrenoreceptors and is thus devoid of sedative, blood-pressure-lowering side effects of E-GA. Treatment of mice with Z-GA (10 mg/kg) before acetaminophen overdose and up to 6 h post APAP administration prevented liver injury and suppressed the elevation of serum ALT levels. Mechanistically, hepatoprotective effects of both isomers are similar and partly attributed to attenuation of the ER stress and oxidative stress in the liver. The results of this study suggest that Z-GA may be a safer, effective antidote for the clinical management of acute liver injury resulting from acetaminophen overdose. It also raises a tantalizing possibility of a prophylactic combination of the geometric isomer of the approved drug guanabenz with acetaminophen in a clinical setting.

[1]  Wei He,et al.  Rosiglitazone Protects against Acetaminophen-Induced Acute Liver Injury by Inhibiting Multiple Endoplasmic Reticulum Stress Pathways , 2022, BioMed research international.

[2]  I. Papet,et al.  Activation of the eIF2α-ATF4 Pathway by Chronic Paracetamol Treatment Is Prevented by Dietary Supplementation with Cysteine , 2022, International journal of molecular sciences.

[3]  R. Andrade,et al.  Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy , 2022, Cell Death & Disease.

[4]  Swati S. More,et al.  LC-MS/MS determination of guanabenz E/Z isomers and its application to in vitro and in vivo DMPK profiling studies. , 2021, Journal of pharmaceutical and biomedical analysis.

[5]  M. Mori,et al.  Administration of small-molecule guanabenz acetate attenuates fatty liver and hyperglycemia associated with obesity , 2020, Scientific Reports.

[6]  Swati S. More,et al.  Guanabenz Attenuates Acetaminophen-Induced Liver Toxicity and Synergizes Analgesia in Mice. , 2020, Chemical research in toxicology.

[7]  S. Kannan,et al.  Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer , 2019, EClinicalMedicine.

[8]  R. Wek.  Role of eIF2α Kinases in Translational Control and Adaptation to Cellular Stress. , 2018, Cold Spring Harbor perspectives in biology.

[9]  Hongbo Hu,et al.  Mechanisms of acetaminophen-induced liver injury and its implications for therapeutic interventions , 2018, Redox biology.

[10]  Swati S. More,et al.  Hepatoprotective Effect of ψ-Glutathione in a Murine Model of Acetaminophen-Induced Liver Toxicity. , 2017, Chemical research in toxicology.

[11]  H. Jaeschke,et al.  Oxidative stress during acetaminophen hepatotoxicity: Sources, pathophysiological role and therapeutic potential , 2016, Redox biology.

[12]  Mila Ljujic,et al.  The integrated stress response , 2016, EMBO reports.

[13]  S. Perrin,et al.  Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS , 2015, PloS one.

[14]  Russ B Altman,et al.  PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses , 2015, Pharmacogenetics and genomics.

[15]  Mitchell R. McGill,et al.  Lower susceptibility of female mice to acetaminophen hepatotoxicity: Role of mitochondrial glutathione, oxidant stress and c-jun N-terminal kinase. , 2014, Toxicology and applied pharmacology.

[16]  R. Urrutia,et al.  Acetaminophen and NAPQI are toxic to auditory cells via oxidative and endoplasmic reticulum stress-dependent pathways , 2014, Hearing Research.

[17]  June Uebeler,et al.  Guanabenz Interferes with ER Stress and Exerts Protective Effects in Cardiac Myocytes , 2014, PloS one.

[18]  K. Reddy,et al.  Acetaminophen-related hepatotoxicity. , 2013, Clinics in liver disease.

[19]  Takao Iwawaki,et al.  CHOP is a critical regulator of acetaminophen-induced hepatotoxicity. , 2013, Journal of hepatology.

[20]  M. Rieder,et al.  Acetaminophen overdose in children , 2012, Canadian Medical Association Journal.

[21]  L. Glimcher,et al.  IRE1α activation protects mice against acetaminophen-induced hepatotoxicity , 2012, The Journal of experimental medicine.

[22]  Mitchell R. McGill,et al.  Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: Lessons learned from acetaminophen hepatotoxicity , 2012, Drug metabolism reviews.

[23]  P. Walter,et al.  The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation , 2011, Science.

[24]  William M. Lee.  Acetaminophen toxicity: Changing perceptions on a social/medical issue , 2007, Hepatology.

[25]  A. Malmberg,et al.  Models of Nociception: Hot‐Plate, Tail‐Flick, and Formalin Tests in Rodents , 2007, Current protocols in neuroscience.

[26]  Hiderou Yoshida,et al.  Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6alpha and XBP1. , 2007, Developmental cell.

[27]  P. Walter,et al.  Signal integration in the endoplasmic reticulum unfolded protein response , 2007, Nature Reviews Molecular Cell Biology.

[28]  Y. Takei,et al.  Role of apoptosis in acetaminophen hepatotoxicity , 2007, Journal of gastroenterology and hepatology.

[29]  Yu-Jui Yvonne Wan,et al.  Acetaminophen metabolism does not contribute to gender difference in its hepatotoxicity in mouse. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[30]  I. Whyte,et al.  The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N-acetylcysteine. , 2005, Annals of emergency medicine.

[31]  H. Jaeschke,et al.  Mitochondrial permeability transition in acetaminophen‐induced necrosis and apoptosis of cultured mouse hepatocytes , 2004, Hepatology.

[32]  William M. Lee.  Acetaminophen and the U.S. acute liver failure study group: Lowering the risks of hepatic failure , 2004, Hepatology.

[33]  J M Ward,et al.  Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. , 1998, Toxicology and applied pharmacology.

[34]  F. Guengerich,et al.  Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. , 1993, Chemical research in toxicology.

[35]  S. Nelson.  Molecular Mechanisms of the Hepatotoxicity Caused by Acetaminophen , 1990, Seminars in liver disease.

[36]  C. Lieber,et al.  Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. , 1989, Archives of biochemistry and biophysics.

[37]  M. Rawlins,et al.  ADVERSE REACTIONS TO N-ACETYLCYSTEINE , 1984, The Lancet.

[38]  N. Deangelis,et al.  Guanabenz degradation products and stability assay. , 1979, Journal of pharmaceutical sciences.

[39]  A. Larson.  Acetaminophen hepatotoxicity. , 2007, Clinics in liver disease.

[40]  K. Lasseter,et al.  Pharmacokinetics of Guanabenz in Patients with Impaired Liver Function , 1984, Journal of cardiovascular pharmacology.